Market Place
Sourcing Support
Pierre And Scorpion Dose First Patient In PFL-241 Trial Lung Cancer
08 Oct 2024 //
BUSINESSWIRE
Scorpion Presents STX-478 Data For Solid Tumors At ESMO Congress 2024
15 Sep 2024 //
BUSINESSWIRE
Scorpion To Present STX-478 Phase 1/2 Data At ESMO Congress 2024
19 Aug 2024 //
BUSINESSWIRE
Scorpion Therapeutics Raises $150M Series C For Precision Oncology Pipeline
16 Jul 2024 //
BUSINESSWIRE
OnKure hitches Reneo’s ride to Nasdaq, with $65M PIPE to boot
13 May 2024 //
FIERCE BIOTECH
Scorpion Therapeutics Appoints Adam Friedman as Chief Executive Officer
04 Jan 2024 //
BUSINESSWIRE
Axel Hoos and Michael Streit depart Scorpion
04 Jan 2024 //
FIERCE BIOTECH
Scorpion Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor
24 Oct 2023 //
BUSINESSWIRE
Scorpion Therapeutics Presents Preclinical Data for STX-241
13 Oct 2023 //
BUSINESSWIRE
Scorpion and Pierre Announce First Patient Dosed in Phase 1/2 Trial of STX-721
10 Oct 2023 //
PR NEWSWIRE
Scorpion Therapeutics Announces First Patient Dosed in Ph1/2 Trial of STX-478
02 May 2023 //
BUSINESSWIRE
Scorpion bags $553M deal for preclinical lung cancer assets
05 Apr 2023 //
FIERCE BIOTECH
Scorpion and Pierre Announce Collaboration to Co-Develop STX-721 and STX-241
04 Apr 2023 //
BUSINESSWIRE
Scorpion Therapeutics Nominates STX-241 as EGFR Inhibitor Development Candidate
03 Apr 2023 //
BUSINESSWIRE
Scorpion Presents Preclinical Data for Potential Best-in-Class PI3K? Inhibitor
08 Dec 2022 //
BUSINESSWIRE
Scorpion to Present Preclinical Data for Mutant-Selective PI3K? Inhibitor
21 Nov 2022 //
BUSINESSWIRE
Scorpion Announces Formation of World-Class Clinical Scientific Advisory Board
07 Nov 2022 //
BUSINESSWIRE
Scorpion to Present Data for Next-Generation Exon 20 Mutant EGFR Inhibitor
12 Oct 2022 //
BUSINESSWIRE
Scorpion Therapeutics Appoints Michael Streit, M.D. as Chief Medical Officer
12 Sep 2022 //
BUSINESSWIRE
Scorpion named by Fierce Biotech as one of its “Fierce 15” Biotech Companies
12 Sep 2022 //
BUSINESSWIRE
Axel Hoos wants to reinvent small-molecule drugs at Scorpion
19 Jul 2022 //
FIERCEBIOTECH
Scorpion Therapeutics Nominates STX-721 as EGFR-EXON-20 Development Candidate
29 Jun 2022 //
BUSINESSWIRE
Scorpion Therapeutics Announces Discovery Scientific Advisory Board
02 Jun 2022 //
BUSINESSWIRE
Scorpion Therapeutics Appoints Saurabh Saha to its Board of Directors
04 Apr 2022 //
BUSINESSWIRE
AstraZeneca, Scorpion enter agreement for novel cancer treatments
12 Jan 2022 //
ASTRAZENECA
Gary Glick`s Odyssey begins with $218M for 7 assets
08 Dec 2021 //
PHARMALIVE
Scorpion Therapeutics Reveals Highly-selective Lead Programs TMutant PI3K?
29 Nov 2021 //
BUSINESSWIRE
Scorpion Therapeutics Appoints Brian Piper as Chief Financial Officer
22 Nov 2021 //
BUSINESSWIRE
GSK oncology head leaves for biotech Scorpion—Chutes & Ladders
09 Jul 2021 //
FIERCEBIOTECH
Scorpion Therapeutics Announces New CEO Axel Hoos, M.D., Ph.D.
07 Jul 2021 //
BUSINESSWIRE
Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing
07 Jan 2021 //
BUSINESSWIRE
